Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 1, 2009, Pages 122-129

  Bianchi, L ^a   Baroli, A ^a   Marzoli, L ^a   Verusio, C ^a   Chiesa, C ^b   Pozzi, L ^a,c  

^a BUSTO ARSIZIO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

153Sm EDTMP; 99m Tc MDP; Bone metastases; Internal dosimetry; Radionuclide therapy

Indexed keywords

LEXIDRONAM SAMARIUM SM 153; MEDRONATE TECHNETIUM TC 99M; ANALGESIC AGENT; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE;

ADULT; ALGORITHM; ARTICLE; BLEEDING; BONE MARROW TOXICITY; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CALCULATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSIMETRY; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; FEVER; HEMATOPOIESIS; HUMAN; LEUKOCYTE COUNT; MALE; PALLIATIVE THERAPY; PROSTATE CANCER; RELIABILITY; SOFT TISSUE; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; BLOOD; BONE TUMOR; CLINICAL TRIAL; METABOLISM; METASTASIS; PAIN; RADIOMETRY; TIME; WHOLE BODY IMAGING;

ANALGESICS, NON-NARCOTIC; BONE NEOPLASMS; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; RADIOMETRY; TECHNETIUM TC 99M MEDRONATE; TIME FACTORS; WHOLE BODY IMAGING;

EID: 57249095837     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0926-7     Document Type: Article

References (24)

1. V Yau E Chow L Davis 2004 Pain management in cancer pain with bone metastases remains a challenge J Pain Symptom Manag 27 1 3
2. K Lote A Walloe A Bjersand 1986 Bone metastases: prognosis, diagnosis, and treatment Acta Radiol Oncol 25 227
3. IR Garret 1993 Bone destruction in cancer Semin Oncol 20 4
4. Bonica JJ. Treatment of cancer pain: current status and future needs. In: Fields HL, Dubner R, Cerbero F, editors. Advances in Pain Research and Therapy. vol 9. New York: Raven; 1985. p. 589-616.
5. CL Maini S Bergomi L Romano R Sciuto 2004 153 Sm-EDTMP for bone palliation in skeletal metastasis Eur J Nucl Med Mol Imaging 31 Suppl 1 S171 S178
6. JE Bayouth DJ Macey LP Kasi FV Fossella 1994 Dosimetry ad toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases J Nucl Med 35 63 69
7. JH Turner A Martindale P Sorby EL Heterhington RF Fleay RF Hoffmann 1989 Samarium 153-EDTMP therapy of disseminated skeletal metastases Eur J Nucl Med 15 784 795
8. G Bauman M Charette R Reid J Sathya 2005 Radiopharmaceutical for the palliation of painful bone metastases-a systematic review Radiother Oncol 75 258 270
9. A Darfemou P Colamussi M Giganti 2001 A multicenter observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer Eur J Nucl Med Mol Imaging 28 788 798
10. 89Sr and/or external radiotherapy Urology 50 747 753
11. JE Bayouth DJ Macey PL Kasi FV Fossella 1994 Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases J Nucl Med 35 63 69
12. Butti I, Nicolini G. Dosimetria nella terapia del dolore osseo. In: Atti del VII Congresso Nazionale AIMN, Palermo; 2004.
13. P Anderson G Wiseman A Dispenzieri 2002 High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases J Clin Oncol 20 189 196
14. R Macklis J Lasher 1999 Palliative radiotherapy for skeletal metastases: cost-substitution analyses and economic impact J Oncol Manag 8 17 22
15. V Damerla S Packianahan P Boerner 2005 Recent developments in nuclear medicine in the management of bone metastases Am J Clin Oncol 28 513 520
16. Loevinger R, Berman M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet no. 1. New York: Society of Nuclear Medicine; 1975.
17. MG Stabin 1996 MIRDOSE: personal computer software for internal dose assessment in nuclear medicine J Nucl Med 37 538 546
18. JF Early C Collins M Stabin C Vernon S Petersdorf M Baker 1993 Samarium-153-EDTMP biodistribution and dosimetry estimation J Nucl Med 34 1031 1036
19. ML Bartlett M Webb S Durrant 2002 Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies Eur J Nucl Med 29 1470 1477
20. 153Sm-EDTMP in patients with metastatic bone disease J Nucl Med 42 230 236
21. 153Sm-EDTMP red marrow dosimetry based on urine collection only Eur J Nucl Med Mol Imaging 33 Suppl 2 S173
22. S Albert JS Ben KA Werner 1997 Dose response relationship and multiple dose efficacy and toxicity of Samarium-153-EDTMP in metastatic cancer to bone Rad Oncol 43 175 179
23. W Brenner H BohuslavizkiK N Sieweke S Tinnemeyer M Clausen E Henze 1997 Quantification of diphosphonate uptake based on conventional bone scanning Eur J Nucl Med 24 1284 1290
24. M Farhanghi RA Holmes WA Volkert KW Logan A Singh 1992 Samarium-153-EDTMP pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer J Nucl Med 33 1451 1458